Russ Lebovitz

Russ Lebovitz, MD, PhD, is CEO and Co-Founder of Amprion, where he leads the company's mission to advance precision medicine for neurodegenerative diseases through biomarker-driven diagnostics. Before entering executive leadership, he spent more than 15 years as a senior scientist and research physician. Dr. Lebovitz has held faculty appointments at Baylor College of Medicine and Fox Chase Cancer Center and earned his MD and PhD from Washington University School of Medicine.

Articles by Russ Lebovitz

Patient connected to brain scan.

| 4 min read

ByRuss Lebovitz

Why neurodegenerative disease drug development needs more than one measurement

Multimodal approaches could help drug developers connect disease biology with clinical outcomes and better understand why treatments succeed or fail.

Page 1 of 1 - 1 Total Items

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.

Mapping cancer signaling at single cell resolution

Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.

Application Note

Illustration of an antibody intertwined with a DNA double helix.

Mapping immune disease variants at genome scale

Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.

Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.

From absorption to metabolism: predicting human oral drug exposure

Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.